Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis

Microbiome

Table 1 Baseline characteristics of patients with benign prostatic hyperplasia, non-metastatic prostate cancer or metastatic prostate cancer

Variables	BPH (n = 20)	nmPCa (n = 10) n (%) or median (IQR)	mPCa (n=5)	P value
Age (years)	70.5 (63–76.75)	69.5 (66.5–75)	68 (65–74)	0.21
BMI (kg/m²)	22.11 (19.06–26.58)	25.21 (23.26–27.87)	23.88 (19.80–26.67)	0.387
PSA (ng/mL)	4.12 (2.14–10.30)	17.36 (12.98–79.74)	67.66 (42.55–4146.35)	<0.001^a
IL6^b (pg/mL)	8 (3.58–10.65)	15.5 (10.65–21.65)	13.5 (-)	0.087
LUTS	18 (90)	7 (70)	3 (60)	0.21
Gleason score group
G1 (3+3)		1 (10)
G2 (3+4)		1 (10)
G3 (4+3)		2 (20)
G4 (4+4, 3+5, 5+3)		4 (40)
G5 (4+5, 5+4, 5+5)		2 (20)	5 (100)

BPH benign prostatic hyperplasia, nmPCa non-metastatic prostate cancer, mPCa metastatic prostate cancer, IQR interquartile range, PSA prostate-specific antigen, LUTS lower urinary tract symptoms
^aKruskal-Wallis test: BPH vs nmPCa (p = 0.005), BPH vs mPCa (p < 0.001), mPCa vs nmPCa (p = 0.657)
^bAvailable data: BPH (n = 12), nmPCa (n = 6), mPCa (n = 2). Analysis was performed by the total available patients

ISSN: 2049-2618